Nanjing Vazyme Biotech Co., Ltd. Class A

As of June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A carries a market capitalization of 8.97B, placing it among publicly traded companies globally. Its enterprise value stands at 7.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nanjing Vazyme Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A has 516.99M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A maintains a current ratio of 3.99, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A recorded an income tax benefit of -4.37M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A's stock has gained approximately 24.35% over the past 52 weeks. The 50-day moving average sits at 22.73, while the 200-day moving average is 17.63.

As of June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A holds 2.51B in cash and equivalents against 671.57M in total debt, resulting in a net debt position of 99.10M. Total book value stands at 3.61B, with working capital of 2.53B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Nanjing Vazyme Biotech Co., Ltd. Class A paid dividends of 0.40 per share.

Nanjing Vazyme Biotech Co., Ltd. Class A's most recent stock split took place on June 3, 2026 with a 10:13 split ratio.